SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Gland Pharma - Quaterly Results

21 Jan 2022 Evaluate
The company witnessed a 23.73% growth in the revenue at Rs. 10633.25 millions for the quarter ended December 2021 as compared to Rs. 8594.19 millions during the year-ago period.A good growth in profit of 33.94% reported to Rs. 2733.84  millions over Rs. 2041.07 millions of corresponding previous quarter.OP of the company witnessed a marginal growth to 3949.35 millions from 2993.62 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 10633.25 8594.19 23.73 32976.94 25751.28 28.06 34628.76 26332.40 31.51
Other Income 456.69 351.30 30.00 1587.06 875.62 81.25 1347.76 1391.68 -3.16
PBIDT 3949.35 2993.62 31.93 13209.14 10621.15 24.37 14370.43 10946.35 31.28
Interest 11.83 11.59 2.07 32.08 23.90 34.23 34.11 71.82 -52.51
PBDT 3937.52 2982.03 32.04 13177.06 10597.25 24.34 14336.32 10874.53 31.83
Depreciation 278.34 249.65 11.49 792.21 738.58 7.26 987.80 945.87 4.43
PBT 3659.18 2732.38 33.92 12384.85 9858.67 25.62 13348.52 9928.66 34.44
TAX 925.34 691.31 33.85 3123.06 2493.13 25.27 3378.47 2200.08 53.56
Deferred Tax 5.02 -1.25 -501.60 46.85 -11.93 -492.71 1.20 -318.21 -100.38
PAT 2733.84 2041.07 33.94 9261.79 7365.54 25.74 9970.05 7728.58 29.00
Equity 164.30 163.28 0.62 164.30 163.28 0.62 163.59 154.95 5.58
PBIDTM(%) 37.14 34.83 6.63 40.06 41.25 -2.88 41.50 41.57 -0.17

Gland Pharma Share Price

1795.80 59.80 (3.44%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×